跳至主要内容
临床试验/JPRN-UMIN000000849
JPRN-UMIN000000849已完成4 期

A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined with Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection - ET Study

International Medical Center of Japan0 个研究点目标入组 240 人开始时间: 2007年10月15日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • •-Current malabsorption condition, -Prior use of lamivudine for hepatitis B treatment, -Positive serology of Hepatitis B surface antigen, -Patients who have following abnormal laboratory results within 6 weeks prior enrollment; 1)alanine aminotransferaseis is more than 2.5 times higher of upper normal limit 2)estimated glomerular filtration rate is less than 60ml/min by Cockcroft-Gault equation 3)serum phosphate level is less than 2.0mg/dl -Patients with hemophilia, diabetes mellitus which require pharmacological treatment, congestive heart failure, cardiomyopathy or other serious medical condition -Patients in pregnancy, breast feeding, -Patients who are taking medicaitions contraindicated for combine use with study medicine -Patients whose primary care physicians consider inadequate to be enrolled

研究者

发起方
International Medical Center of Japan

相似试验

进行中(未招募)
不适用
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005631-20-NLAllergan Ltd300
进行中(未招募)
1 期
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 15.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005631-20-BEAllergan Ltd300
进行中(未招募)
不适用
Comparison of efficacy and safety of OZURDEX versus Lucentis in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005631-20-ITALLERGAN LIMITED300
进行中(未招募)
1 期
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005631-20-ESAllergan Ltd363
进行中(未招募)
不适用
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005631-20-ATAllergan Ltd300
A Randomized, Open Label, Multicenter Study... | 临床试验